Author

Kaan Kavakli

Ege university Children Hospital - Cited by 5,154 - Hematology

Biography

Kaan Kavakli currently is working in Ege University Medical Faculty, Child Health and Diseases Department, Pediatric Hematology Division, Turkey. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his/her valuable service towards the scientific community with his extensive research work.
Title
Cited by
Year
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results
AD Shapiro, P Angchaisuksiri, J Astermark, G Benson, G Castaman, ...Blood, The Journal of the American Society of Hematology 134 (22), 1973-1982, 2019201
127
2019
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
P Monagle, AWA Lensing, K Thelen, I Martinelli, C Male, A Santamaría, ...The Lancet Haematology 6 (10), e500-e509, 2019201
52
2019
Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients
T Lissitchkov, B Madan, C Djambas Khayat, N Zozulya, C Ross, M Karimi, ...Journal of Thrombosis and Haemostasis 18 (4), 815-824, 2020202
23
2020
Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in …
A Srivastava, S Rangarajan, K Kavakli, R Klamroth, G Kenet, L Khoo, ...Blood 138, LBA-3, 2021202
14
2021
Efficacy and safety of fitusiran prophylaxis, an siRNA therapeutic, in a multicenter phase 3 study (ATLAS-INH) in people with hemophilia A or B, with inhibitors (PwHI)
G Young, A Srivastava, K Kavakli, C Ross, J Sathar, H Tran, R Wu, J Sun, ...Blood 138, 4, 2021202
12
2021
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the …
H Yaish, T Matsushita, M Belhani, V Jiménez‐Yuste, K Kavakli, ...Haemophilia 26 (1), 64-72, 2020202
11
2020
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
AD Shapiro, P Angchaisuksiri, J Astermark, G Benson, G Castaman, ...Blood Advances 6 (11), 3422-3432, 2022202
10
2022
Prophylaxis in children with haemophilia in an evolving treatment landscape
ME Mancuso, C Male, G Kenet, K Kavakli, C Königs, J Blatný, ...Haemophilia 27 (6), 889-896, 2021202
10
2021
Evaluation of bleeding phenotype of inherited factor VII deficiency in children with a bleeding assessment tool and global assays
E Toret, Y Ay, TH Karapinar, Y Oymak, K Kavakli, RC VerginJournal of Pediatric Hematology/Oncology 42 (6), e52-e530, 2020202
7
2020
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
G Young, A Srivastava, K Kavakli, C Ross, J Sathar, CW You, H Tran, ...The Lancet 401 (1038), 1427-1437, 2023202
6
2023
Surgeries and diagnostic procedures in hemophilia patients on concizumab prophylaxis: results from the phase 2 Explorer4 and Explorer5 trials
Surgeries and diagnostic procedures in hemophilia patients on concizumab prophylaxis: results from the phase 2 Explorer and Explorer5 trialsAP Wheeler, G Benson, H Eichler, SM Tønder, K Cepo, VJ Yuste, ...Blood 138, 35, 2021202
4
2021
Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia
NG Andersson, R Wu, M Carcao, S Claeyssens-Donadel, R Kobelt, ...British journal of haematology 190 (2), e101-e10, 2020202
4
2020
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
A Srivastava, S Rangarajan, K Kavakli, R Klamroth, G Kenet, L Khoo, ...The Lancet Haematology 10 (5), e322-e332, 2023202
4
2023
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency
F Peyvandi, G Auerswald, SK Austin, R Liesner, K Kavakli, MTÁ Román, ...Blood Reviews 50, 1008, 2021202
3
2021
The value of ultrasonography in detecting early arthropathic changes and contribution to the clinical approach in patients of hemophilia
İ Tamsel, K Kavakli, SS Özbek, İ Hekimsoy, C Balkan, F Şahin, S TamselJournal of Clinical Ultrasound 50 (), 428-42, 2022202
3
2022
Management of haemophilia A with inhibitors: a regional cross‐talk
F Peyvandi, K Kavakli, A El‐Beshlawy, S RangarajanHaemophilia 28 (6), 950-961, 2022202
3
2022
Fertility in patients with thalassemia and outcome of pregnancies: a Turkish experience
B Akıncı, AŞ Yaşar, NÖ Karadaş, ZÖ Siviş, HH Özdemir, DY Karapınar, ...Turkish Journal of Hematology 6 (4), 274, 2019201
3
2019
Plasma‐derived factor X concentrate compassionate use for hereditary factor X deficiency: Long‐term safety and efficacy in a retrospective data‐collection study
JN Huang, R Liesner, SK Austin, K Kavakli, C AkaneziResearch and Practice in Thrombosis and Haemostasis 5 (5), e1550, 010
2
2021
Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with severe hemophilia A without inhibitors: results from the phase 2 explorer5 trial
Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with severe hemophilia A without inhibitors: results from the phase explorer5 trialH Eichler, P Angchaisuksiri, J Astermark, G Benson, K Cepo, P Chowdary, ...Blood 134, 417, 01901
2
2019
Management of breakthrough bleeds during concizumab prophylaxis in patients with haemophilia A/B with and without inhibitors in phase 3 clinical trials
J Astermark, P Angchaisuksiri, K Kavakli, M Zak, S SeremetisHaemophilia 8, 70-71, 0
2
2022

Referred From: https://scholar.google.com/citations?hl=en&user=MeEx3mYAAAAJ

Cited by
Citations 5154
h-index 36
i10-index 114
Recommended Journals
Open Access Journals